Frontiers in Immunology (Jul 2021)

Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort

  • Chaojun Hu,
  • Chaojun Hu,
  • Siting Li,
  • Siting Li,
  • Zhijuan Xie,
  • Zhijuan Xie,
  • Hanxiao You,
  • Hanxiao You,
  • Hui Jiang,
  • Hui Jiang,
  • Yu Shi,
  • Yu Shi,
  • Wanting Qi,
  • Wanting Qi,
  • Jiuliang Zhao,
  • Jiuliang Zhao,
  • Qian Wang,
  • Qian Wang,
  • Xinping Tian,
  • Xinping Tian,
  • Mengtao Li,
  • Mengtao Li,
  • Yan Zhao,
  • Yan Zhao,
  • Xiaofeng Zeng,
  • Xiaofeng Zeng

DOI
https://doi.org/10.3389/fimmu.2021.648881
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundDiagnosis of antiphospholipid syndrome (APS) is based on the positivity of laboratory criteria antiphospholipid antibodies (aPLs). Test results for aPLs could be contradictory among different detection methods as well as commercial manufacturers. This study aimed to assess and compare the diagnostic and analytic performances of four commercial assays prevalently used in China.MethodsA total of 313 patients including 100 patients diagnosed with primary APS, 52 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum IgG, IgM, and IgA for aCL, and aβ2GPI antibodies were detected with two ELISA and two CLIA systems, and test system with the best diagnostic value was explored of its correlation with key clinical features.ResultsCLIA by YHLO Biotech Co. was considered as the system with the best predictive power, where 58.55 and 57.89% of APS patients were positive for aCL or aβ2GPI for at least one antibody (IgG or IgM or IgA). Overall, CLIA showed better performance characteristics than traditional ELISA test systems.ConclusionCLIA was considered as a better platform for aPL detection in APS diagnosis. A combination of other detection platforms could assist in differential diagnosis as well as in identifying high-risk patients.

Keywords